Business News • PR NewsWire • Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, in Ulcerative Colitis Presented in DDW2014 |
Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, in Ulcerative Colitis Presented in DDW2014 |
|
|
Phase 2a Clinical Study Data of AJM300, Oral alpha 4 Integrin Antagonist, in Ulcerative Colitis Presented in DDW2014
TOKYO, May 13, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) announced on May 13 that the Phase 2a results of an oral alpha 4 integrin antagonist, AJM300, in patients with ulcerative colitis were presented in the Joint...
View More : http://www.prnewswire.com/news-releases/phase-2a-clinical-study-data-of-ajm300-oral-alpha-4-integrin-antagonist-in-ulcer...
|
|
|